Targets › HRHR
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on HRHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Ebastine H1 receptor antagonist | HRHR | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
Metastatic Castration-resistant Prostate Cancer (1)
small molecule (1)
Copenhagen University Hospital, Rigshospitalet (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.